Immatics (NASDAQ:IMTX) Releases Quarterly Earnings Results, Beats Expectations By $0.51 EPS

Immatics (NASDAQ:IMTX) announced its earnings results on Thursday. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.51, Zacks reports. The company had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%.

Immatics Price Performance

Shares of IMTX stock traded down $0.08 during trading on Friday, reaching $4.63. The company’s stock had a trading volume of 574,228 shares, compared to its average volume of 625,304. The stock’s 50-day moving average price is $4.97 and its 200 day moving average price is $7.54. The company has a market capitalization of $552.62 million, a price-to-earnings ratio of -7.02 and a beta of 0.83. Immatics has a 1-year low of $4.06 and a 1-year high of $13.77.

Institutional Trading of Immatics

An institutional investor recently raised its position in Immatics stock. Bank of America Corp DE lifted its holdings in shares of Immatics (NASDAQ:IMTX) by 166.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,575 shares of the company’s stock after acquiring an additional 2,231 shares during the period. Bank of America Corp DE’s holdings in Immatics were worth $25,000 at the end of the most recent reporting period. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.